by Crestone, Inc. | Sep 12, 2019 | Press Releases
Sep 12, 2019 – Announcement: Crestone, Inc. Secures NIH Funding for Phase 2 Clinical Trial of Novel Antibiotic Candidate, CRS3123 to Treat C. difficile infection. Learn More:...
by Crestone, Inc. | Apr 14, 2019 | Events
Presentation Overview Crestone, Inc. presents at the 29th ECCMID in Amsterdam, Netherlands. Oral Session: Mode of Action, Spectrum of Activity, and Preclinical in vivo Efficacy of CRS0540, a PolC DNA Polymerase Inhibitor of Resistant Gram-positive...
by Crestone, Inc. | Sep 12, 2018 | Events
Crestone presents at Healthcare Capital and Connections Summit, Shanghai, China: CRS3123 for the Treatment of C. difficile Infection, and other Pipeline Programs
by Crestone, Inc. | Sep 4, 2018 | Events
ESCMID/ASM Conference Presentation Details Crestone presents a poster at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance: Lead Development of PolC Polymerase Inhibitors against Resistant Gram‐positive...
by Crestone, Inc. | Jun 10, 2018 | Events
ASM Microbe 2018 Presentation Details Crestone presents an invited slide talk at ASM Microbe 2018 (Atlanta, GA) Optimization and Lead Selection of Benzothiazole Amide Analogs toward a Novel Antimycobacterial Agent. Link to...
